Literature DB >> 35716277

Meta analysis of bioactive compounds, miRNA, siRNA and cell death regulators as sensitizers to doxorubicin induced chemoresistance.

Sruthi Sritharan1, Sampurna Guha1, Snoopy Hazarika1, Nageswaran Sivalingam2.   

Abstract

Cancer has presented to be the most challenging disease, contributing to one in six mortalities worldwide. The current treatment regimen involves multiple rounds of chemotherapy administration, alone or in combination. The treatment has adverse effects including cardiomyopathy, hepatotoxicity, and nephrotoxicity. In addition, the development of resistance to chemo has been attributed to cancer relapse and low patient overall survivability. Multiple drug resistance development may be through numerous factors such as up-regulation of drug transporters, drug inactivation, alteration of drug targets and drug degradation. Doxorubicin is a widely used first line chemotherapeutic drug for a myriad of cancers. It has multiple intracellular targets, DNA intercalation, adduct formation, topoisomerase inhibition, iron chelation, reactive oxygen species generation and promotes immune mediated clearance of the tumor. Agents that can sensitize the resistant cancer cells to the chemotherapeutic drug are currently the focus to improve the clinical efficiency of cancer therapy. This review summarizes the recent 10-year research on the use of natural phytochemicals, inhibitors of apoptosis and autophagy, miRNAs, siRNAs and nanoformulations being investigated for doxorubicin chemosensitization.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer; Chemoresistance; Chemosensitization; Doxorubicin; miRNA; siRNA

Mesh:

Substances:

Year:  2022        PMID: 35716277     DOI: 10.1007/s10495-022-01742-z

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   5.561


  184 in total

Review 1.  Liposomal drug delivery systems: from concept to clinical applications.

Authors:  Theresa M Allen; Pieter R Cullis
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

2.  Chemotherapy: Preventing competitive release.

Authors:  Sarah Seton-Rogers
Journal:  Nat Rev Cancer       Date:  2016-04       Impact factor: 60.716

3.  Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040: a population-based study.

Authors:  Brooke E Wilson; Susannah Jacob; Mei Ling Yap; Jacques Ferlay; Freddie Bray; Michael B Barton
Journal:  Lancet Oncol       Date:  2019-05-08       Impact factor: 41.316

Review 4.  Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC.

Authors:  Alex Chang
Journal:  Lung Cancer       Date:  2010-10-16       Impact factor: 5.705

Review 5.  Doxorubicin, DNA torsion, and chromatin dynamics.

Authors:  Fan Yang; Sheila S Teves; Christopher J Kemp; Steven Henikoff
Journal:  Biochim Biophys Acta       Date:  2013-12-19

Review 6.  Role of anthracyclines in the era of targeted therapy.

Authors:  Hernán Cortés-Funes; Cyntia Coronado
Journal:  Cardiovasc Toxicol       Date:  2007       Impact factor: 3.231

Review 7.  The role of iron in anthracycline cardiotoxicity.

Authors:  Elena Gammella; Federica Maccarinelli; Paolo Buratti; Stefania Recalcati; Gaetano Cairo
Journal:  Front Pharmacol       Date:  2014-02-26       Impact factor: 5.810

Review 8.  Metabolic carbonyl reduction of anthracyclines - role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and chemosensitizing agents.

Authors:  Kamil Piska; Paulina Koczurkiewicz; Adam Bucki; Katarzyna Wójcik-Pszczoła; Marcin Kołaczkowski; Elżbieta Pękala
Journal:  Invest New Drugs       Date:  2017-03-10       Impact factor: 3.850

Review 9.  Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.

Authors:  Derek W Edwardson; Rashmi Narendrula; Simon Chewchuk; Kyle Mispel-Beyer; Jonathan P J Mapletoft; Amadeo M Parissenti
Journal:  Curr Drug Metab       Date:  2015       Impact factor: 3.731

10.  Cancer Statistics, 2020: Report From National Cancer Registry Programme, India.

Authors:  Prashant Mathur; Krishnan Sathishkumar; Meesha Chaturvedi; Priyanka Das; Kondalli Lakshminarayana Sudarshan; Stephen Santhappan; Vinodh Nallasamy; Anish John; Sandeep Narasimhan; Francis Selvaraj Roselind
Journal:  JCO Glob Oncol       Date:  2020-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.